Lin Johnny L, Balbas John, Richardson E Greer
Foot Ankle Int. 2008 Aug;29(8):781-6. doi: 10.3113/FAI.2008.0781.
There are few long-term studies on the non-operative treatment of Stage II Posterior Tibial Tendon Dysfunction (PTTD). The purpose of this study is to describe the natural history and determine the efficacy of non-operative treatment of Stage II PTTD using clinical outcome scores.
Patients with Stage II PTTD treated with a Double Upright Ankle Foot Orthosis (DUAFO) with a minimum followup of 7 years were identified retrospectively. Patients were evaluated with the AOFAS Ankle/Hindfoot Score, SF-36, Foot Function Index (FFI), Visual Analog Scale (VAS) for pain, and a custom questionnaire in addition to a comprehensive physical examination.
Thirty-three feet in 32 patients were included with an average followup of 8.6 years. Success defined as being brace-free and avoiding surgery was 69.7%. Five patients (15.2%) were unable to completely wean from a brace. Five patients went on to surgery. The mean AOFAS and FFI score was 78.4 and 18.4, respectively. Compared to national norms, SF-36 subscores for each age sub-category showed no significant difference in any of the age groups (p<0.05). Average VAS pain scale score was 1.9. Satisfaction was rated as "satisfied" in 20 patients (60.6%), "satisfied with minor reservations" in 11 patients (33.3%), partially satisfied in one (3.0%), and "unsatisfied" in one (3.0%). None of the patients rated as "satisfied with major reservations".
Treatment of Stage II PTTD with a DUAFO has been shown to be a viable alternative to surgery with a high likelihood of adequate function, avoidance of surgery, and being brace-free at 7- to 10-year followup.
关于II期胫后肌腱功能障碍(PTTD)非手术治疗的长期研究较少。本研究的目的是描述其自然病程,并使用临床结局评分确定II期PTTD非手术治疗的疗效。
回顾性确定采用双直立式踝足矫形器(DUAFO)治疗且随访至少7年的II期PTTD患者。除全面的体格检查外,还使用美国足踝外科协会(AOFAS)踝/后足评分、SF-36健康调查量表、足部功能指数(FFI)、疼痛视觉模拟量表(VAS)以及一份定制问卷对患者进行评估。
纳入32例患者的33只足,平均随访8.6年。定义为无需支具并避免手术的成功率为69.7%。5例患者(15.2%)无法完全停用支具。5例患者接受了手术。AOFAS和FFI的平均评分分别为78.4和18.4。与全国常模相比,各年龄亚组的SF-36子评分在任何年龄组中均无显著差异(p<0.05)。VAS疼痛量表平均评分为1.9。20例患者(60.6%)将满意度评为“满意”,11例患者(33.3%)评为“基本满意”,1例(3.0%)评为“部分满意”,1例(3.0%)评为“不满意”。没有患者评为“非常不满意”。
已证明使用DUAFO治疗II期PTTD是一种可行的手术替代方案,在7至10年的随访中,具有获得足够功能、避免手术且无需支具的高可能性。